- Home
- PTGX vs GBDC Comparison
PTGX vs GBDC Comparison
Compare PTGX & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- GBDC
- Stock Information
- Founded
- PTGX 2006
- GBDC 2009
- Country
- PTGX United States
- GBDC United States
- Employees
- PTGX N/A
- GBDC N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- GBDC Finance: Consumer Services
- Sector
- PTGX Health Care
- GBDC Finance
- Exchange
- PTGX Nasdaq
- GBDC Nasdaq
- Market Cap
- PTGX 3.3B
- GBDC 4.0B
- IPO Year
- PTGX 2016
- GBDC 2010
- Fundamental
- Price
- PTGX $51.07
- GBDC $14.85
- Analyst Decision
- PTGX Strong Buy
- GBDC Buy
- Analyst Count
- PTGX 8
- GBDC 4
- Target Price
- PTGX $70.13
- GBDC $15.50
- AVG Volume (30 Days)
- PTGX 608.4K
- GBDC 1.1M
- Earning Date
- PTGX 08-06-2025
- GBDC 08-04-2025
- Dividend Yield
- PTGX N/A
- GBDC 11.79%
- EPS Growth
- PTGX N/A
- GBDC N/A
- EPS
- PTGX 0.80
- GBDC 1.41
- Revenue
- PTGX $209,180,000.00
- GBDC $877,342,000.00
- Revenue This Year
- PTGX N/A
- GBDC $21.93
- Revenue Next Year
- PTGX $53.09
- GBDC N/A
- P/E Ratio
- PTGX $63.42
- GBDC $10.50
- Revenue Growth
- PTGX N/A
- GBDC 31.97
- 52 Week Low
- PTGX $33.31
- GBDC $12.68
- 52 Week High
- PTGX $60.60
- GBDC $16.01
- Technical
- Relative Strength Index (RSI)
- PTGX 37.60
- GBDC 46.32
- Support Level
- PTGX $52.03
- GBDC $14.68
- Resistance Level
- PTGX $54.81
- GBDC $14.93
- Average True Range (ATR)
- PTGX 2.11
- GBDC 0.23
- MACD
- PTGX -0.52
- GBDC -0.06
- Stochastic Oscillator
- PTGX 8.78
- GBDC 33.33
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.